Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”

Saved in:

Bibliographic Details
Published in:	International journal of cancer Vol. 154; no. 4; pp. 764 - 765
Main Authors:	Kim, Yoo‐Na, Joung, Je‐Gun, Park, Eunhyang, Kim, Jae‐Weon, Lee, Jung Bok, Lim, Jinyeong, Kim, Sunghoon, Choi, Chel Hun, Kim, Hee Seung, Chung, Jongsuk, Kim, Byoung‐Gie, Lee, Jung‐Yun
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 15-02-2024 Wiley Subscription Services, Inc
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer Carcinoma, Ovarian Epithelial Female Humans Neoplasm Recurrence, Local - drug therapy Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Phthalazines - adverse effects
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	0020-7136 1097-0215
DOI:	10.1002/ijc.34786